Henry Schein (NASDAQ:HSIC) Releases Earnings Results, Beats Estimates By $0.04 EPS

Henry Schein (NASDAQ:HSIC) released its earnings results on Tuesday. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04, Zacks reports. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%. Henry Schein updated its FY 2026 guidance to 5.230-5.370 EPS.

Henry Schein Stock Performance

Henry Schein stock opened at $80.57 on Tuesday. The company has a current ratio of 1.40, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54. The firm has a market cap of $9.49 billion, a P/E ratio of 25.50, a P/E/G ratio of 2.37 and a beta of 0.88. Henry Schein has a 1-year low of $60.56 and a 1-year high of $82.80. The firm has a 50-day moving average of $77.43 and a 200-day moving average of $71.78.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. lifted its holdings in Henry Schein by 4.1% in the 3rd quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock worth $314,043,000 after buying an additional 184,763 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Henry Schein by 8.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,816,317 shares of the company’s stock valued at $212,865,000 after acquiring an additional 220,149 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Henry Schein by 11.3% during the third quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock valued at $167,453,000 after acquiring an additional 256,156 shares in the last quarter. Southpoint Capital Advisors LP lifted its stake in Henry Schein by 38.9% in the fourth quarter. Southpoint Capital Advisors LP now owns 2,500,000 shares of the company’s stock worth $188,950,000 after acquiring an additional 700,000 shares during the period. Finally, Bank of Montreal Can boosted its holdings in Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after acquiring an additional 2,087,666 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Analyst Ratings Changes

HSIC has been the subject of a number of recent research reports. Wells Fargo & Company boosted their price objective on shares of Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Morgan Stanley boosted their price target on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Barclays started coverage on Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price for the company. Finally, Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $78.75.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.